Valley National Advisers Inc. Acquires 2,748 Shares of Stryker Corporation $SYK

Valley National Advisers Inc. grew its holdings in Stryker Corporation (NYSE:SYK) by 48.3% in the 3rd quarter, Holdings Channel reports. The fund owned 8,442 shares of the medical technology company’s stock after purchasing an additional 2,748 shares during the quarter. Valley National Advisers Inc.’s holdings in Stryker were worth $2,325,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Gables Capital Management Inc. bought a new position in shares of Stryker during the 2nd quarter valued at about $25,000. Kilter Group LLC acquired a new position in shares of Stryker in the 2nd quarter valued at approximately $25,000. Highland Investment Advisors LLC acquired a new position in shares of Stryker in the 2nd quarter valued at approximately $25,000. Cornerstone Financial Management LLC grew its position in shares of Stryker by 66.0% in the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after purchasing an additional 31 shares during the period. Finally, Compass Financial Management LLC bought a new stake in Stryker during the 2nd quarter worth approximately $27,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

SYK opened at $307.65 on Friday. The business’s 50-day moving average price is $295.23 and its two-hundred day moving average price is $311.93. Stryker Corporation has a 1 year low of $267.00 and a 1 year high of $389.33. The company has a market capitalization of $118.01 billion, a price-to-earnings ratio of 31.88, a P/E/G ratio of 1.98 and a beta of 0.78. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts expect that Stryker Corporation will post 14.93 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on SYK. Barclays upgraded shares of Stryker to a “strong-buy” rating in a report on Wednesday, October 7th. Wells Fargo & Company cut their price target on shares of Stryker from $418.00 to $348.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 9th. TD Cowen reduced their price target on shares of Stryker from $355.00 to $298.00 and set a “hold” rating for the company in a report on Tuesday, September 22nd. Citigroup reduced their price target on shares of Stryker from $399.00 to $360.00 and set a “buy” rating for the company in a report on Thursday, September 10th. Finally, BTIG Research lowered their price objective on shares of Stryker from $358.00 to $316.00 and set a “buy” rating for the company in a research report on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $369.00.

Insider Activity at Stryker

In other Stryker news, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the transaction, the insider owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This represents a 6.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Debra King sold 826 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.